trending Market Intelligence /marketintelligence/en/news-insights/trending/ycnb9octslmeqh6ohern8a2 content esgSubNav
In This List

PSivida's eye disease therapy lowers inflammation recurrence

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


PSivida's eye disease therapy lowers inflammation recurrence

Watertown, Mass.-based pSivida Corp.'s eye inflammation treatment Durasert showed a significant reduction in inflammation recurrence rate at 12 months.

In a second phase 3 trial of 153 patients, 36.6% of Durasert-treated patients had a recurrence of posterior segment uveitis compared to 71.2% of patients in the sham group.

Posterior segment uveitis is a chronic, non-infectious inflammatory disease affecting the posterior segment of the eye, often involving the retina, and may lead to blindness.

Durasert, a three-year treatment for posterior segment uveitis, is a tiny micro-insert that is injected into the eye and delivers very small doses of a drug on a sustained basis.

PSivida previously reported that six months after treatment, only 21.8% of Durasert-treated patients saw a recurrence compared to 53.8% of patients in the sham group.